Literature DB >> 7398195

Catechol-O-methyltransferase activity: a determinant of levodopa response.

D K Reilly, L Rivera-Calimlim, D Van Dyke.   

Abstract

In 14 patients with Parkinson's disease on long-term therapy the erythrocyte catechol-O-methyltransferase activity was found to correlate with the average plasma concentration ratio of 3-O-methyldopa to levodopa and with the fasting plasma concentration ratio of 3-O methyldopa to levodopa. Patients with the higher erythrocyte catechol-O-methyltransferase activities were those with less favorable clinical responses to levodopa. Since erythrocyte catechol-O-methyltransferase activity may reflect the activity of that enzyme in the major metabolizing tissues, catechol-O-methyltransferase activity would seem to be a significant determinant of response to levodopa.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7398195     DOI: 10.1038/clpt.1980.161

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  24 in total

1.  Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.

Authors:  H Baas; A G Beiske; J Ghika; M Jackson; W H Oertel; W Poewe; G Ransmayr
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-10       Impact factor: 10.154

2.  Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease.

Authors:  M Contin; R Riva; P Martinelli; F Albani; A Baruzzi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Ethnic differences in drug disposition and responsiveness.

Authors:  A J Wood; H H Zhou
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

4.  Acetylator polymorphism in Parkinson's disease.

Authors:  J M Ladero; F J Jimenez; J Benitez; M J Fernandez-Gundin; C Martinez; A Llerena; J Cobaleda; J J Muñoz
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 5.  Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.

Authors:  John P M Finberg
Journal:  J Neural Transm (Vienna)       Date:  2018-11-01       Impact factor: 3.575

6.  Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.

Authors:  Oscar Solís; Jose-Rubén García-Montes; Patricia Garcia-Sanz; Antonio S Herranz; Maria-José Asensio; Gina Kang; Noboru Hiroi; Rosario Moratalla
Journal:  Neurobiol Dis       Date:  2017-03-16       Impact factor: 5.996

Review 7.  Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase.

Authors:  Richard M Weinshilboum
Journal:  Cell Mol Neurobiol       Date:  2006-06-29       Impact factor: 5.046

8.  The role of 3-O-methyldopa in the side effects of L-dopa.

Authors:  Eun-Sook Y Lee; Hongtao Chen; Jennifer King; Clivel Charlton
Journal:  Neurochem Res       Date:  2007-08-24       Impact factor: 3.996

Review 9.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  Catechol-O-methyltransferase (COMT) gene variants: possible association of the Val158Met variant with opiate addiction in Hispanic women.

Authors:  Bronson E Oosterhuis; K Steven LaForge; Dmitri Proudnikov; Ann Ho; David A Nielsen; Robert Gianotti; Sandra Barral; Derek Gordon; Suzanne M Leal; Jurg Ott; Mary Jeanne Kreek
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-09-05       Impact factor: 3.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.